✦ LIBER ✦

Coadministration of the Vasopressin-2 Receptor Antagonist Tolvaptan and B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal or Neurohumoral Function in Experimental Congestive Heart Failure

✍ Scribed by Lisa C. Costello-Boerrigter; Guido Boerrigter; Gail J. Harty; John C. Burnett Jr.

Book ID: 119214540
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 49 KB
Volume: 13
Category: Article
ISSN: 1532-8414
DOI: 10.1016/j.cardfail.2007.06.609

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Coadministration of B-type natriuretic p

Coadministration of B-type natriuretic peptide and the vasopressin-2 receptor antagonist tolvaptan: a novel physiologic strategy to enhance water and sodium excretion without adversely affecting renal or neurohumoral function in experimental congestive heart failure

✍ Lisa C Costello-Boerrigter; Guido Boerrigter; Gail J Harty; John C Burnett 📂 Article 📅 2007 🏛 BioMed Central 🌐 English ⚖ 404 KB

Publish with Bio Med Central and every scientist can read your work free of charge "BioMed Central will be the most significant development for disseminating the results of biomedical researc h in our lifetime.

Co-Targeting of the V2 Receptor with Tol

Co-Targeting of the V2 Receptor with Tolvaptan and the Natriuretic Peptide A-Receptor with B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal Function: A Novel Physiologic Approach to Sodium and Water Retention in Experimental Heart Failure

✍ Lisa C. Costello-Boerrigter; Guido Boerrigter; Gail J. Harty; John C. Burnett Jr 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 76 KB